HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Similar Items

• P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
  by: Moodie Z, et al.
  Published: (2009-10-01)
• Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
  by: Kathryn L Hopkins, et al.
  Published: (2014-01-01)
• P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
  by: Roux S, et al.
  Published: (2009-10-01)
• Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa.
  by: Erica Maxine Lazarus, et al.
  Published: (2014-01-01)
• Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.
  by: Rephaim Mpofu, et al.
  Published: (2021-01-01)